Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1183 studies found for:    ESR1
Show Display Options
Rank Status Study
1 Recruiting Study of ESR1 Mutations in Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Intervention: Biological: Determination of ESR1 mutations
2 Unknown  Validation of [18F]FES for Imaging of Brain Estrogen Receptors
Conditions: Psychiatric/Mood Disorder | Patient;   Estrogen Receptor Levels;   Premenopausal;   Postmenopausal
Intervention: Procedure: FES-PET
3 Completed Estrogen Receptors and Chronic Venous Disease
Conditions: Estrogen Excess;   Varicose Veins
Intervention: Procedure: Venous Surgery
4 Not yet recruiting Phase II Treatment of Metastatic Breast Cancer With Fulvestrant or Tamoxifen
Condition: Metastatic Breast Cancer
Interventions: Drug: Fulvestrant;   Drug: Tamoxifen
5 Active, not recruiting An Open Label Study of Postmenopausal Women With Oestrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) With Exemestane, With Exploratory Epigenetic Marker Analysis
Condition: Oestrogen Receptor Positive Advanced Breast Cancer
Interventions: Drug: RAD001;   Drug: Exemestane
6 Completed
Has Results
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Conditions: Estrogen Receptor Positive Tumor;   Breast Cancer
Interventions: Drug: eribulin mesylate;   Drug: capecitabine
7 Completed
Has Results
A Study of the Effect of Estrogen on Estrogen Receptor Biomarkers in Healthy Postmenopausal Women (0000-094)(COMPLETED)
Condition: Postmenopause
Interventions: Drug: Comparator: placebo;   Drug: Comparator: Estrace
8 Active, not recruiting BKM120 and Fulvestrant for Treating Postmenopausal Patients With Estrogen Receptor-Positive Stage IV Breast Cancer
Conditions: Estrogen Receptor-positive Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: BKM120;   Drug: Fulvestrant;   Procedure: biopsy
9 Recruiting Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer
Conditions: Estrogen Receptor Positive;   HER2/Neu Negative;   Recurrent Breast Carcinoma;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Tamoxifen Citrate;   Drug: Z-Endoxifen Hydrochloride
10 Recruiting Pembrolizumab, Letrozole, and Palbociclib in Treating Patients With Stage IV Estrogen Receptor Positive Breast Cancer With Stable Disease That Has Not Responded to Letrozole and Palbociclib
Conditions: Estrogen Receptor Positive;   HER2/Neu Negative;   Postmenopausal;   Recurrent Breast Carcinoma;   Stage IV Breast Cancer
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Letrozole;   Drug: Palbociclib;   Biological: Pembrolizumab
11 Recruiting Fluorestradiol (FES) PET/CT for Imaging Estrogen Receptor Status
Condition: Breast Cancer
Interventions: Drug: Fluorestradiol (FES);   Procedure: PET/CT Imaging
12 Active, not recruiting Ruxolitinib in Estrogen Receptor Positive Breast Cancer
Condition: Estrogen-receptor Positive Invasive Metastatic Breast Cancer
Interventions: Drug: Ruxolitinib;   Drug: Exemestane
13 Recruiting Adjuvant Endocrine Therapy for Estrogen Receptor-beta Positive Triple Negative Breast Cancer
Condition: Female Breast Cancer
Intervention: Drug: Toremifene; Anastrozole
14 Terminated
Has Results
Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer
Conditions: Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: goserelin acetate;   Drug: letrozole;   Drug: anastrozole;   Drug: chemotherapy;   Procedure: Surgery
15 Completed Fulvestrant (FASLODEX™) as a Treatment in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer
Condition: Breast Cancer
Intervention: Drug: Fulvestrant
16 Recruiting The Efficacy and Safety of a Selective Estrogen Receptor Beta Agonist (LY500307) for Negative Symptoms and Cognitive Impairment Associated With Schizophrenia
Condition: Schizophrenia
Interventions: Drug: LY500307 150mg;   Drug: LY500307 75mg;   Drug: Placebo
17 Completed Estrogen Receptor Beta Agonists (Eviendep) and Polyp Recurrence
Condition: Adenocarcinoma of Colon Recurrent
Interventions: Dietary Supplement: Eviendep (CM&D Pharma Limited, UK);   Dietary Supplement: Maltodextrins
18 Completed
Has Results
Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
Condition: Breast Cancer
Interventions: Drug: Everolimus;   Drug: Exemestane;   Drug: Everolimus Placebo
19 Recruiting Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers
Condition: Advanced or Metastatic ER+ Breast Cancer
Interventions: Drug: LSZ102;   Drug: LEE011;   Drug: BYL719
20 Not yet recruiting Assessment of Safety and Efficacy of Estetrol in Postmenopausal Women With Advanced Estrogen Receptor Positive (ER+) Breast Cancer
Condition: Breast Neoplasms
Interventions: Drug: Phase I: estetrol;   Drug: Phase II: estetrol

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years